Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Feb 8;14:1108116. doi: 10.3389/fimmu.2023.1108116

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2023 Müller-Jensen, Knauss, Ginesta Roque, Schinke, Maierhof, Bartels, Finke, Rentzsch, Ulrich, Mohr, Stenzel, Endres, Boehmerle and Huehnchen

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Serum autoantibody profiles in cancer patients with irAE-n and controls. (A) Frequency and specification of neuromuscular autoantibodies of 41 cancer patients before (upper left) and six weeks after (middle left) ICI treatment initiation who did not develop high-grade (= CTCAE ≥ 3) irAEs and 24 ICI-treated cancer patients with irAE-n (lower left). (B) Frequency and specification of brain-reactive autoantibodies of 44 cancer patients before (upper right) and six weeks after (middle right) ICI treatment initiation who did not develop high-grade (CTCAE ≥ 3) irAEs and 29 ICI-treated cancer patients with irAE-n (lower right). Ab, autoantibody; AchR, acetylcholine receptor; CASPR2, contactin-associated protein-like 2; GABA_BR, gamma-aminobutyric-acid B receptor; GFAP, glial fibrillary acidic protein; Homer-3, Homer protein homolog 3; ICI, immune checkpoint inhibitor; irAEs, immune related adverse events; irAE-n, neurological immune related adverse event; ITPR1, inositol 1,4,5-trisphosphate receptor 1; LRP4, low-density lipoprotein receptor-related protein 4; MuSK, muscle-specific tyrosine kinase; NMDAR, N-methyl-D-aspartate receptor; P/Q VGCC, P/Q-type voltage gated calcium channel; RyR, ryanodine receptor; Zic4, zinc finger 4.